|
The Epigenetic Advance: CellCentric Licences Novel Discovery Programme to Takeda |
CellCentric, the world-leading epigenetics company based in Cambridge UK, has announced details of a significant deal, which takes epigenetic science closer towards clinical application and commercialisation in the field of cancer. The company has a considerable IP resource in novel epigenetic targets. It is from this portfolio that CellCentric has granted to Takeda Pharmaceutical Company Limited an exclusive licence to develop a key cancer programme. More details here.
|
